Extracted from this filing and checked against the source text.
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Humacyte, Inc. entered into Placement Agreement with Titan Partners Group LLC, a division of American Capital Partners, LLC (effective 2026-03-19).
- Action
- entry
- Agreement
- underwriting
- Counterparty
- Titan Partners Group LLC, a division of American Capital Partners, LLC
- Effective
- 2026-03-19
Exact text from the filing
On March 19, 2026, the Company also entered into a placement agent agreement (the “Placement Agreement”) with Titan Partners Group LLC, a division of American Capital Partners, LLC, as the placement agent (the “Placement Agent”), in connection with the Offering.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Humacyte, Inc. entered into Purchase Agreements with certain investors valued at 25,000,000 shares ... at a price of $0.80 per share (effective 2026-03-19).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- certain investors
- Value
- 25,000,000 shares ... at a price of $0.80 per share
- Effective
- 2026-03-19
Exact text from the filing
On March 19, 2026, Humacyte, Inc. (the “Company”) entered into certain securities purchase agreements (the “Purchase Agreements”) pursuant to which the Company agreed to issue and sell to certain investors in a registered direct offering (the “Offering”) 25,000,000 shares of the Company’s common stock, $0.0001 par value per share, at a price of $0.80 per share (the “Shares”).
View on SEC.gov